New Coverage

Bearish Valeant Pharmaceuticals Intl Inc (VRX) Analyst Sent Shares Tumbling

Goldman Sachs’ Dana Flanders sheds new insights on Valeant from a bearish standpoint, spotting 5% in loss potential for the stock.

Twitter Inc (TWTR) Gains a New Bull Who Advises to “Get in Early” on the Stock

Summit Redstone’s Jonathan Kees thinks the market is underestimating Twitter’s turnaround.

This Analyst Finds It Best to Wait on Buying Square Inc (SQ) Until More Attractive Entry Point Comes Around

Cowen’s Georgios Mihalos makes a neutral case on Square’s opportunity, giving kudos to its “Build with Square” integrated strategy, but seeing growth opportunities priced into the current stock price.

This Healthcare Analyst Pounds the Table on Revance Therapeutics Inc (RVNC)

Guggenheim’s Rohit Vanjani puts a price tag on Revance Therapeutics.

Bluebird Bio Inc Gains a New Bull; John Newman Drawn to bb2121’s Long-Term Potential

Canaccord’s John Newman sees 24% upside potential for BLUE shares.

Celsion Corporation (CLSN) Stock Fires to the Roof on Back of New Bull’s Confident Bet

Oppenheimer’s Hartaj Singh sees 227% upside potential for CLSN.

Meet Apple Inc.’s (AAPL) New Skeptic

Wells Fargo’s Aaron Rakers sees 14% upside potential for AAPL stock, but spotlights volatility down the line.

Helios and Matheson Analytics Inc’s (HMNY) Many Monetization Ways Have Attracted a New Bull

Maxim is confident that HMNY’s recent 52% purchase of MoviePass will usher in commercial leverage.

Dynavax Technologies Corporation (DVAX) Gains a Cantor Bull on Back of Compelling HBV Opportunity

Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts